Elamipretide
Verdict card (component)
✓ Established | for Barth syndrome (accelerated approval); other indications remain Investigational
A mitochondria-targeting tetrapeptide that became the first FDA-approved mitochondrial-targeted therapeutic when it received accelerated approval as Forzinity in September 2025 for Barth syndrome — an ultra-rare X-linked cardioskeletal disease affecting ~150 patients in the US. Engineered to localize selectively to the inner mitochondrial membrane via cardiolipin binding, where it stabilizes electron transport chain function and reduces oxidative damage. The Barth syndrome approval was supported by the TAZPOWER trial; broader mitochondrial-disease applications (primary mitochondrial myopathy, dry AMD) continue in development with mixed-to-positive results.
Evidence signal row
- ✓ FDA accelerated approval September 2025 — Forzinity for Barth syndrome ≥30 kg
- ✓ First-in-class mitochondria-targeted therapeutic
- ! Other indications still Investigational — MMPOWER-3 missed primary endpoint in mitochondrial myopathy; dry AMD ongoing
Our verdict (3 sentences)
Elamipretide’s regulatory arc finally landed in 2025 with FDA accelerated approval for Barth syndrome — the first approved mitochondria-targeted therapeutic, and a rare-disease success after a long and complicated development history. We rate it Established for Barth syndrome (the approved indication, supported by TAZPOWER trial data); for the broader mitochondrial-disease applications it’s been investigated for — primary mitochondrial myopathy where Phase 3 missed, and dry AMD where Phase 3 is still running — the verdict remains Investigational. Continued accelerated-approval status is contingent on confirmatory trials, so the Barth syndrome verdict could move depending on the post-marketing data.
Mechanism
Elamipretide (originally known as MTP-131, SS-31, or Bendavia) is a synthetic 4-amino-acid peptide with the sequence D-Arg-2′,6′-dimethyl-Tyr-Lys-Phe-NH2. The non-natural amino acids and amide-capped C-terminus provide protease resistance and the specific charge profile needed for mitochondrial targeting.
The molecule’s selective mitochondrial localization is the key mechanistic feature. The alternating cationic and aromatic residues create an amphipathic structure that binds cardiolipin — a phospholipid uniquely concentrated in the inner mitochondrial membrane. After cellular uptake, elamipretide accumulates 1,000–5,000-fold in mitochondria versus cytoplasm.
At the inner membrane, elamipretide:
- Stabilizes cardiolipin-cytochrome c interactions
- Reduces cardiolipin peroxidation under oxidative stress
- Preserves cristae structure and electron transport chain efficiency
- Reduces mitochondrial reactive oxygen species generation
Net effect in mitochondrial dysfunction contexts: improved ATP production, reduced oxidative damage, preserved mitochondrial morphology.
The mechanism is well-characterized in cell culture and animal models — multiple independent groups have replicated the cardiolipin-binding biology.
What the evidence shows
Phase 2 MMPOWER-1, MMPOWER-2 (primary mitochondrial myopathy, 2017–2018): Open-label and short-duration RCT showed modest improvements in 6-minute walk distance, fatigue, and muscle function.
Phase 3 MMPOWER-3 (Karaa et al, Neurology 2023): 218 patients with primary mitochondrial myopathy, 24-week double-blind RCT. Did not meet primary endpoint (change in 6-minute walk distance) at the prespecified analysis. Some secondary endpoints showed trends but the primary failure was the regulatory-relevant result.
Barth syndrome (TAZPOWER trial): Trial in this rare X-linked cardiolipin-remodeling disorder. Knee extensor muscle strength improved from baseline during the open-label portion. After multiple FDA review cycles (initial Complete Response Letters requiring additional analyses, then NDA resubmission accepted), the FDA granted accelerated approval as Forzinity in September 2025 for Barth syndrome patients weighing ≥30 kg. Continued approval is contingent upon verification of clinical benefit in confirmatory trial(s) — standard accelerated-approval framework. EMA orphan designation was granted in May 2021; full EMA approval has not yet been granted as of this review.
Dry age-related macular degeneration (Phase 3 ReGAIN trial): Reading out late 2026; if positive, would represent a much larger commercial indication.
Heart failure with preserved ejection fraction (HFpEF): Phase 2 data not strong enough to advance.
Acute kidney injury after cardiac surgery (RECOMMEND trial): Did not meet primary endpoint.
The pattern: clear mechanism, occasional positive trials in narrow populations (Barth syndrome), broader application trials have generally missed their primary endpoints. The drug is doing something; whether what it’s doing translates to clinical benefit in the populations originally targeted has been less consistent than hoped.
Dosing literature
Trial protocols have used:
- 40 mg subcutaneous daily (standard dose in mitochondrial myopathy trials)
- Some Phase 2 ophthalmologic protocols use intravitreal administration for AMD
- Pediatric dosing weight-adjusted in Barth syndrome (which affects children)
There is no approved dose for general use in the US — only the EMA-approved Barth syndrome indication has formal dosing guidance.
Risks and adverse events
Reported in clinical trials:
- Injection site reactions (very common; subcutaneous injections produce significant local irritation, sometimes leading to discontinuation)
- Headache
- Mild GI symptoms (nausea, abdominal pain)
- Fatigue (which may be confounded by the underlying mitochondrial disease)
Less common:
- Hypertension elevations
- Mild hematologic effects
Long-term safety: Multi-year exposure data exists from MMPOWER extension cohorts. No major safety signals beyond the local injection site issues. The overall profile is favorable for a chronically-administered peptide.
The injection site reaction problem has been substantial enough that it impacts adherence in real-world use; alternative formulations (long-acting depot, oral formulations) are under development.
Regulatory status
| Region | Status | Notes |
|---|---|---|
| United States | Approved (Forzinity) | FDA accelerated approval September 19, 2025, for Barth syndrome in patients ≥30 kg. First FDA-approved mitochondria-targeted therapeutic. Continued approval contingent on confirmatory trials. |
| European Union | Orphan designation only | EU/3/21/2430 granted May 20, 2021. Full EMA approval not yet granted. |
| United Kingdom | Not approved | |
| Other markets | Not approved | Stealth running expanded access programs in some jurisdictions for patients <30 kg or in countries without approval. |
Manufacturer: Stealth BioTherapeutics. The company has had a complicated regulatory journey with this molecule; multiple Phase 3 trials, multiple FDA review cycles, and ongoing development across several indica
Quick Facts
| Also Known As | SS-31, Bendavia, MTP-131, Szeto-Schiller peptide 31 |
|---|---|
| Sequence | D-Arg-Dmt-Lys-Phe-NH2 |
| Molecular Formula | C32H49N9O5 |
| Molecular Weight | 639.8 Da |
| PubChem CID | 11764719 |
Mechanism of Action
Elamipretide's primary mechanism of action centers on its interaction with cardiolipin on the inner mitochondrial membrane, leading to improved mitochondrial efficiency and reduced reactive oxygen species (ROS) production.
Cardiolipin Binding and Stabilization: Elamipretide contains a sequence motif that allows it to selectively bind to cardiolipin. This binding helps stabilize the structure of cardiolipin-rich membrane domains, particularly at cristae junctions. This stabilization is crucial for maintaining the integrity of mitochondrial supercomplexes (assemblies of electron transport chain proteins), which are essential for efficient electron transfer and ATP synthesis.
Reduction of Electron Leak and ROS: By stabilizing electron transport chain supercomplexes, elamipretide reduces electron leak, a primary source of damaging superoxide radicals. This leads to a significant decrease in mitochondrial ROS production, alleviating oxidative stress within the organelle and the cell.
Improvement of ATP Synthesis: The stabilization of mitochondrial structure and reduction in proton leak across the inner membrane improves the proton motive force. This enhances the efficiency of ATP synthase, leading to increased ATP production even under conditions of stress, such as ischemia or metabolic demand.
Inhibition of Mitochondrial Permeability Transition Pore (mPTP) Opening: By scavenging ROS directly at its site of production and stabilizing cardiolipin, elamipretide helps prevent the pathological opening of the mPTP. The mPTP is a non-specific channel whose opening leads to mitochondrial swelling, rupture of the outer membrane, and the release of pro-apoptotic factors, culminating in cell death. Elamipretide's action helps maintain mitochondrial integrity and prevents this cascade.
Research Applications
Cardiovascular Diseases
Research in models of myocardial ischemia-reperfusion injury, heart failure, and atrial fibrillation has shown that elamipretide can preserve left ventricular function, reduce infarct size, and improve mitochondrial respiration. It appears to protect cardiomyocytes from death during ischemic insult and improve cardiac efficiency in failing hearts by enhancing mitochondrial bioenergetics and reducing fibrosis.
Primary Mitochondrial Myopathies
Clinical and preclinical studies, particularly in Barth syndrome and other disorders of cardiolipin remodeling, have demonstrated that elamipretide can improve mitochondrial function in skeletal muscle. Outcomes include increased maximal ATP production, improved exercise tolerance, and reduced markers of oxidative stress, addressing the core bioenergetic deficit in these genetic conditions.
Neurodegenerative Disorders
In models of Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS), elamipretide has shown neuroprotective effects. It reduces neuronal loss, improves motor and cognitive function, and decreases markers of neuroinflammation and oxidative damage. The mechanism is linked to protecting neuronal and glial mitochondria, thereby preserving synaptic function and neuronal viability.
Renal Protection
Studies in models of acute kidney injury and chronic kidney disease indicate that elamipretide can protect renal tubular cells. It reduces apoptosis, preserves mitochondrial structure in proximal tubules, and mitigates fibrosis, leading to improved renal function and histology following ischemic or toxic insults.
Ocular Diseases
Preclinical research in models of dry age-related macular degeneration and Leber's hereditary optic neuropathy suggests a potential role for elamipretide in protecting retinal pigment epithelium and retinal ganglion cells. The benefit is attributed to the rescue of mitochondrial function in these highly metabolically active tissues, reducing photoreceptor cell death.
Safety & Side Effects
Data from animal toxicology studies and human clinical trials indicate elamipretide is generally well-tolerated. In human trials, reported adverse events have been mostly mild and comparable to placebo, with no dose-limiting toxicities identified in the studied ranges. The most commonly reported side effects in clinical trials include infusion site reactions (e.g., pain, erythema), headache, dizziness, and nausea. No significant effects on vital signs, ECG parameters, or laboratory safety markers (hematology, clinical chemistry) have been consistently attributed to the drug. Theoretical concerns, based on its mechanism, are minimal as it does not directly alter nuclear gene expression or major systemic signaling pathways. However, comprehensive long-term safety data in humans beyond 36 weeks of treatment is not yet available.
Dosage Information
This information is derived solely from published preclinical and clinical research protocols and is for research purposes only. In human clinical trials for conditions like primary mitochondrial myopathy and heart failure, intravenous administration has been the primary route. Typical research doses in these trials have ranged from 0.01 mg/kg to 0.25 mg/kg, administered via daily intravenous infusion over periods ranging from 5 days to several weeks. Subcutaneous administration has also been explored in some studies. The frequency is typically once daily, and treatment duration in completed phase 2 trials has extended up to 36 weeks. Optimal dosing, route, and regimen are still under investigation and are condition-dependent.
References
Szeto, H.H., & Schiller, P.W. (2011). Novel therapies targeting inner mitochondrial membrane—from discovery to clinical development. Pharmaceutical Research, 28(11), 2669-2679.
Birk, A.V., et al. (2013). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology, 24(8), 1250-1261.
Chatfield, K.C., et al. (2020). Elamipretide improves mitochondrial function in the skeletal muscle of volunteers with Barth syndrome. Journal of Inherited Metabolic Disease, 43(5), 1074-1084.
Dai, W., et al. (2014). Bendavia, a mitochondria-targeting peptide, improves postinfarction cardiac function, prevents adverse left ventricular remodeling, and restores mitochondria-related gene expression in rats. Journal of Cardiovascular Pharmacology, 64(6), 543-553.
Siegel, M.P., et al. (2013). Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell, 12(5), 763-771.
Zhao, K., et al. (2004). Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. Journal of Biological Chemistry, 279(33), 34682-34690.
Sloan, R.C., et al. (2012). Mitochondrial permeability transition in the diabetic heart: contributions of thiol redox state and mitochondrial calcium to augmented reperfusion injury. Journal of Molecular and Cellular Cardiology, 52(5), 1009-1018.